Sudeep Pharma share price
NSE: SUDEEPPHRMBSE: 544619Chemicals & PetrochemicalsSmall Cap
Last close ₹966.20up ₹4.20 (0.44%)BSE ₹964.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹962.00.
Range of traded prices from listing on 28 Nov 2025 to 23 Oct 2026
₹524.05Low, 21 Jan 2026₹1,378.00High, 7 Sep 2026
- Next results date: the board meets on 28 Oct 2026 to consider: financial results and other business matters.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹10,913 Cr654th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 4 Aug 2026
- 59.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 25 Jun 2026
- 12.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.16%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 4 Aug 2026
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 4 Aug 2026
- 20.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 25 Jun 2026
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,80,83351.0% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 4 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹158 Crdown 13.20%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹41 Crdown 16.38%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 25.6%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Jun 2025Filed 19 Dec | Sep 2025Filed 19 Dec | Dec 2025Filed 6 Feb | Mar 2026Filed 25 Jun | Jun 2026Filed 4 Aug |
|---|---|---|---|---|---|
| Revenue | 125 | 163 | 172 | 182 | 158 |
| Net profit | 31 | 47 | 48 | 49 | 41 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 25.0% | 28.8% | 27.7% | 26.6% | 25.6% |
Consolidated. The 5 quarters from Jun 2025, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Pharmaceutical, food and nutritionPharmaceutical, food and nutrition, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹363 Cr56.5%
- Speciality IngredientsSpeciality Ingredients, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹280 Cr43.5%
Valuation
Today, against the company's own history.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 75% of 207 trading days since Dec 2025.
LowestHighest
Its median10.4Industry median2.5
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 95% of 223 trading days since Nov 2025.
LowestHighest
Its median0.00%Industry median0.54%
Mutual funds holding it
35 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 7 of the 16 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 10
- CutCut. Funds that held fewer shares than at the end of the month before.
- 6
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 18
| Fund | |||
|---|---|---|---|
 Axis Small Cap FundAxis Mutual Fund | 20,02,038 | 0.79% | ₹241.4 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 13,60,000 | 2.79% | ₹164.0 Cr |
 HDFC Manufacturing fundHDFC Mutual Fund | 8,30,000 | 0.97% | ₹100.1 Cr |
| SBI MNC FundSBI Mutual Fund | 6,87,500 | 1.30% | ₹82.9 Cr |
| SBI Comma FundSBI Mutual Fund | 6,86,955 | 6.86% | ₹82.8 Cr |
 Edelweiss Recently Listed Ipo FundEdelweiss Mutual Fund | 3,83,673 | 3.63% | ₹46.3 Cr |
 Aditya Birla Sun Life Small Cap FundAditya Birla Sun Life Mutual Fund | 3,59,797 | 0.71% | ₹43.4 Cr |
| SBI Retirement Benefit Fund - AggressiveSBI Mutual Fund | 3,27,521 | 1.29% | ₹39.5 Cr |
 Trustmf Small Cap FundTrust Mutual Fund | 3,14,018 | 0.98% | ₹37.9 Cr |
 PGIM India Small Cap FundPGIM India Mutual Fund | 2,40,000 | 1.66% | ₹28.9 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Specialty Chemicals, 130 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Sudeep Pharma in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 BASF IndiaBASF | 13,289 | 20.7 | 3.4 | 13.0 | +6.7% | +62.4% | 16.9% | 20.2% | 0.81% |
 Privi Speciality ChemicalsPRIVISCL | 12,696 | – | 9.0 | 20.5 | +21.6% | – | – | 21.3% | 0.31% |
 Anupam Rasayan IndiaANURAS | 12,542 | 71.8 | 3.8 | 24.8 | +51.8% | +41.5% | 5.7% | 6.2% | 0.14% |
 Vinati OrganicsVINATIORGA | 11,102 | 24.8 | 3.5 | 16.7 | +5.1% | +5.4% | 15.1% | 17.3% | 0.79% |
 Elantas Beck IndiaELANTAS | 9,740 | 54.9 | 8.8 | 44.5 | +17.7% | +33.5% | 17.4% | 17.6% | 0.06% |
 Jubilant IngreviaJUBLINGREA | 9,587 | 31.1 | 3.1 | 16.3 | +11.0% | +11.2% | 10.2% | 11.2% | 0.83% |
 Alkyl Amines ChemicalsALKYLAMINE | 8,362 | 37.1 | 5.5 | 23.9 | +5.1% | +20.6% | 15.3% | 17.6% | 0.61% |
 Galaxy SurfactantsGALAXYSURF | 7,877 | 22.3 | 2.9 | 12.9 | +27.1% | +16.1% | 13.9% | 16.2% | 0.99% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹1.50 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 23 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
21 Oct · Analysts
5 Oct · Management
Sep 2026
23 Sep · Analysts
22 Sep · Analysts
16 Sep · Analysts
Sudeep Pharma share price by year
Each calendar year to 2025.Sudeep Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 602.75 | – | 774.15 | 602.75 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 28 Nov 2025.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 960.00 | 975.90 | 917.40 | 966.20 | 947.61 | 3,80,833 | 51.0% |
| 22 Oct 2026 | 976.50 | 987.00 | 953.70 | 962.00 | 965.74 | 1,95,723 | 50.2% |
| 21 Oct 2026 | 1,010.70 | 1,010.70 | 965.20 | 971.60 | 978.24 | 1,55,840 | 48.5% |
| 19 Oct 2026 | 999.00 | 1,016.80 | 964.70 | 1,003.30 | 987.77 | 1,94,805 | 45.5% |
| 16 Oct 2026 | 1,016.00 | 1,030.00 | 991.00 | 1,000.70 | 1,009.05 | 1,25,394 | 54.1% |
| 15 Oct 2026 | 1,070.00 | 1,073.90 | 1,003.90 | 1,008.10 | 1,025.87 | 1,12,751 | 48.5% |
| 14 Oct 2026 | 1,022.00 | 1,060.20 | 998.20 | 1,055.20 | 1,024.00 | 3,50,474 | 41.1% |
| 13 Oct 2026 | 1,030.00 | 1,031.10 | 981.60 | 1,012.20 | 1,001.99 | 4,07,311 | 62.7% |
| 12 Oct 2026 | 1,053.30 | 1,087.00 | 1,008.00 | 1,018.40 | 1,034.95 | 3,15,350 | 51.5% |
| 9 Oct 2026 | 1,110.00 | 1,117.20 | 1,035.80 | 1,050.30 | 1,054.41 | 5,43,547 | 45.9% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Sudeep Pharma Limited
- NSE symbol
- SUDEEPPHRM
- BSE code
- 544619
- ISIN
- INE0QPI01025
- Industry
- Chemicals & Petrochemicals
- Listed
- Nov 2025
- Face value
- ₹1
- CIN
- U24231GJ1989PLC013141
- Corporate identity number, the registrar of companies' code for it